FRI0458 Assessment of Comorbidity in Psoriatic Disease: How Often Should Be Performed?. (15th July 2016)

• Record Type: Journal Article
• Authors: Carmona, L.; Torre-Alonso, J.C.; Moreno, M.; Galíndez, E.; Babío, J.; Zarco, P.; Linares, L.F.; Collantes, E.; Fernández-Barrial, M.; Hermosa, J.C.; Coto, P.; Suárez, C.; Almodόvar, R.; Luelmo, J.; Cárcaba, V.; Castañeda, S.; Otόn, T.; Curbelo, R.; Gratacόs, J.
• Is Part Of: Annals of the rheumatic diseases. Volume 75(2016)Supplement 2
• Page Start: 602
• Page End: 603
• Publication Date: 2016-07-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2016-eular.3484
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Psoriatic disease (PsD) is associated with multiple comorbidities. When establishing management protocols, the periodicity for detection and evaluation of such comorbid conditions needs to be specified. Objectives: To establish guidelines for the follow-up of selected comorbidities in patients with PsD. Methods: An expert panel with specialists in Rheumatology, Internal Medicine, Dermatology and General Practitioners defined the comorbidities with higher impact on PsD based on the existing literature and their experience. The periodicity for detection and monitoring of comorbidities in the Rheumatology setting was established by consensus after iterations and systematic review. Results: The expert panel agreed to evaluate comorbidities as part of routine clinical practice at the time of diagnosis, upon changes in systemic treatment and at follow-up visits (evidence level 5, level of agreement 8.8). In any case, monitoring must be customized depending on the risk profile, morbidity, comorbidities and patient preferences. The following table shows the proposed periodicity for detection, assessment, and monitoring of the most important comorbidities in PsD. Conclusions: This proposal for a periodic assessment of comorbidities in patients with PD allows systematic clinical monitoring of the patient by the Rheumatologist and Dermatologist, and can contribute to the early detection and management of these comorbidities Acknowledgement: The GECOAP project was funded by Merck Sharp & Dohme of Spain Disclosure of Interest: None declared